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Organogenesis requires a balance between self-
renewal and diff  erentiation of the organ’s stem 
cells. This is important not only for producing 
the mature cells essential for its normal func-
tion but also to maintain a pool of multipotent 
stem cells in organs, especially those that un-
dergo continual developmental processes dur-
ing an organism’s lifespan.
Hematopoiesis requires a continuous pro-
duction of progenitors and mature blood 
cells from hematopoietic stem cells (HSCs) 
through diff  erentiation processes. Simultane-
ously, maintenance of the HSC pool occurs 
via cell fate decisions of self-renewal, apop-
tosis/senescence, or diff  erentiation.  Studies 
involving   genetically modifi  ed HSCs such as 
overexpression of HOXB4 (1, 2), Notch1 (3), 
and β-catenin (4) in HSCs have provided evi-
dence of genes that increase HSC self-renewal. 
Although each of these genes increases HSC 
potential when artifi  cially induced, their physi-
ological roles in HSC homeostasis are unclear, 
as mice defi  cient for Hoxb4, β-catenin, and 
Notch1 have been reported to have normal 
HSC content and function (5–7). Further-
more, to date, there has been a lack of studies 
describing genes that are physiologically re-
quired for maintaining the HSC pool in vivo 
and that reciprocally regulate HSC fate in an 
activation state–dependent manner.
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Hematopoietic stem cells (HSCs) sustain lifelong production of all blood cell types through 
fi  nely balanced divisions leading to self-renewal and differentiation. Although several genes 
infl  uencing HSC self-renewal have been identifi  ed, to date no gene has been described 
that, when activated, enhances HSC self-renewal and, when activated, promotes HSC 
differentiation. We observe that the retinoic acid receptor (RAR)𝗄 is selectively expressed 
in primitive hematopoietic precursors and that the bone marrow of RAR𝗄 knockout mice 
exhibit markedly reduced numbers of HSCs associated with increased numbers of more 
mature progenitor cells compared with wild-type mice. In contrast, RAR𝗂 is widely ex-
pressed in hematopoietic cells, but RAR𝗂 knockout mice do not exhibit any HSC or pro-
genitor abnormalities. Primitive hematopoietic precursors overexpressing RAR𝗂 differentiate 
predominantly to granulocytes in short-term culture, whereas those overexpressing RAR𝗄 
exhibit a much more undifferentiated phenotype. Furthermore, loss of RAR𝗄 abrogated 
the potentiating effects of all-trans retinoic acid on the maintenance of HSCs in ex vivo 
culture. Finally, pharmacological activation of RAR𝗄 ex vivo promotes HSC self-renewal, as 
demonstrated by serial transplant studies. We conclude that the RARs have distinct roles in 
hematopoiesis and that RAR𝗄 is a critical physiological and pharmacological regulator of 
the balance between HSC self-renewal and differentiation.
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 We have previously described a novel role for the vita-
min A derivative, all-trans retinoic acid (ATRA), in enhanc-
ing the maintenance of HSCs in ex vivo liquid suspension 
culture (8). ATRA activates the retinoic acid receptors 
(RARs), of which there are three subtypes: RARα, RARβ, 
and RARγ. In these studies, we sought to determine whether 
any of the RARs had a physiological role in the regulation 
of HSCs.
Here, we show that loss of RARγ results in reduced 
numbers of HSCs and increased numbers of more diff  erenti-
ated progenitor cells in the mutant mice. Furthermore, un-
like wild-type HSCs, RARγ null HSCs did not repopulate 
recipients after 14 d of ex vivo culture with ATRA. In con-
trast, loss of the other RAR predominantly expressed in he-
matopoietic cells, RARα, did not result in any hematopoietic 
defects in the mice and ATRA-treated RARα null HSCs 
had comparable repopulating activity to wild-type HSCs cul-
tured with ATRA. Finally, treatment of cultures of highly 
enriched populations of hematopoietic precursors/stem cells 
with ATRA, the natural ligand for RARγ, resulted in in-
creased Notch1 and Hoxb4 expression in these cells accom-
panied by enhanced HSC self-renewal, as shown by increased 
potential of ATRA-treated HSCs to repopulate mice after 
serial transplantation. These results, therefore, demonstrate 
that RARγ is a critical regulator of the balance between HSC 
self-renewal and diff  erentiation; loss of RARγ results in re-
duced numbers of HSCs as the result of enhanced HSC dif-
ferentiation, whereas RARγ activation results in HSC 
self-renewal.
RESULTS
RAR𝗄1 and RAR𝗂 have different effects on hematopoietic 
progenitor cells
RARα and RARγ subtypes are most widely expressed in 
hematopoiesis and loss of both of these RARs results in early 
postnatal lethality accompanied by impaired granulopoiesis 
in vivo (9). To determine which of the RARs may have a 
role in regulating HSCs, expression analysis of the major iso-
forms of the three RAR subtypes was performed in the HSC-
  containing lineage-negative, c-kit–positive, Sca-1–positive 
(LKS+) cells and the lineage-negative, c-kit–positive, Sca-1–
negative (LKS−) cell population, which does not contain 
HSCs (10) and diff  erentiates in response to ATRA treatment 
(11). RARα was expressed in both LKS+ and LKS− cells. In 
contrast, RARβ2 and RARγ1 were expressed preferentially 
by LKS+ (Table S1, available at http://www.jem.org/cgi/
content/full/jem.20052105/DC1). RARβ null mice are es-
sentially normal (12) in contrast with the RARα and RARγ 
null mice, which have profound defects in multiple organs 
(13, 14). Therefore, we focused our attention on a role for 
RARα or RARγ in the regulation of HSCs.
To further defi  ne the roles of RARα and RARγ1 in 
HSCs, we used retroviral vector-mediated gene transduc-
tion to individually overexpress RARα and RARγ1 (15) in 
5-fl  uorouracil pretreated BM and monitored the   proliferation 
and diff  erentiation of the transduced cells during 4 wk of 
culture in cytokine-containing media (see supplemental 
  Materials and methods, available at http://www.jem.org/cgi/
content/full/jem.20052105/DC1). 48 h after the infection, 
the transduction effi   ciencies (GFP+ cells) were 8.8% (con-
trol), 4.3% (RARα), and 4.5% (RARγ1). During the 4 wk 
of culture, cell viabilities of the GFP+ cells within each cul-
ture were similar. Both the control and RARα-overexpress-
ing cells proliferated well in culture, comprising >50% of the 
cells in the cultures at 4 wk (Fig. S1, A–C, available at http://
www.jem.org/cgi/content/full/jem.20052105/DC1). At 
this time point, the RARα-overexpressing cells predomi-
nantly expressed the granulocyte marker, Gr-1 (Fig. S1 D). 
In contrast, cells overexpressing RARγ1 proliferated slowly 
in culture (comprising <2% of the culture), did not express 
Gr-1, were negative for all other lineage markers assessed, 
and expressed high levels of Sca-1 (Fig. S1). Thus, there was 
a marked diff  erence in the proliferation and diff  erentiation of 
the RARα- vs. RARγ1-transduced cells, with the RARα-
transduced cells exhibiting rapid proliferation and diff  eren-
tiation to granulocytes, whereas the RARγ transduced cells 
exhibited much slower proliferation associated with a much 
more immature phenotype.
RAR𝗄 null BM cells have increased numbers of progenitors
To confi  rm that RARα and RARγ have distinct roles in 
hematopoiesis, especially with respect to HSCs, we investi-
gated the multipotential progenitor cell compartment of 
RARα and RARγ+/+, +/−, and −/− single mutant 
mice. BM obtained from the RARα−/− and RARα+/− 
mice had equivalent numbers of immature mixed colonies 
(CFU-granulocyte, erythrocyte, macrophage, megakaryocyte 
[GEMM]) and CFU-spleen (CFU-S) compared with 
RARα+/+ BM (Fig. 1, A and B). In contrast, BM from 
RARγ−/− mice had twofold increased CFU-GEMM and 
threefold increased CFU-S compared with RARγ+/+ BM 
(Fig. 1, C and D; P < 0.05). Further investigation of 
RARγ−/− BM revealed that this was also accompanied by 
signifi  cantly increased numbers of common myeloid pro-
genitors (CMPs) and common lymphoid progenitors (CLPs) 
compared with RARγ+/+ BM (Fig. 1, E and F; P < 0.05).
RAR𝗄 null BM cells contain markedly reduced numbers 
of HSCs
The increased numbers of CFU-GEMM, CFU-S, CMPs, 
and CLPs in the RARγ−/− BM may have resulted from in-
creased numbers of HSCs, or alternatively from enhanced 
proliferation or diff  erentiation of the HSCs into the more 
mature progenitor pool. Therefore, we performed limiting 
dilution assays (16) using BM from wild-type, RARγ+/−, 
RARγ−/−, and RARα−/− mice to compare the numbers 
of transplantable HSCs in these mice. Lethally irradiated (10 
Gy) recipient mice (8–10 mice per cell dose) were injected 
with limiting numbers of donor cells together with 2 × 105 
competing cells, and the frequency of HSCs estimated at 
6 mo posttransplant using Poisson statistics (Fig. S2, available at
http://www.jem.org/cgi/content/full/jem.20052105/DC1).JEM VOL. 203, May 15, 2006  1285
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Mice that had ≥1% multilineage repopulating donor cells 
were considered to be positive for donor cell reconstitu-
tion and those that had <1% donor cells were considered to 
be negative.
The number of long-term repopulating HSCs per femur 
of each genotype is shown in Fig. 2, derived from data given 
in Fig. S2. There was a 3.3-fold reduction in the number of 
HSCs per femur in BM from RARγ−/− mice compared 
with wild-type BM (Fig. 2; P < 0.05). Furthermore, this 
profound decrease occurred in the very primitive, multilin-
eage repopulating HSCs, as repopulation of the myeloid and 
lymphoid lineages was equally aff  ected by loss of RARγ (un-
published data). In marked contrast, there were similar num-
bers of long-term repopulating HSCs per femur in BM from 
RARα−/− mice compared with wild-type BM (Fig. 2).
The reduction in HSCs together with the increased num-
bers of CFU-GEMM, CFU-S, CMPs, and CLPs in RARγ−/− 
BM (Fig. 1, C–F) suggests that the loss of RARγ in 
vivo likely results in enhanced diff  erentiation of HSCs into 
more mature progenitor compartments. Interestingly, the 
RARγ+/− mice also showed signs of haplo-insuffi   ciency 
with respect to their HSC content, having twofold fewer 
HSCs per femur than wild-type mice (Fig. 2; P < 0.05) and 
twofold increased numbers of CFU-S (Fig. 1 D). In marked 
contrast, we did not detect an altered HSC content in 
RARα−/− mice compared with their wild-type littermates 
(Fig. 2). Collectively, these data underscore the importance 
of RARγ in the maintenance of the HSC pool.
Enriched populations of RAR𝗄 null HSCs have reduced 
long-term repopulating potential accompanied 
by increased production of progenitor cells
To further explore a potential role of RARγ in regulating 
HSCs, we assessed the repopulating potential of a more en-
riched population of RARγ-defi  cient HSCs, the LKS+ cell 
population, which are the HSC-containing population used 
in our previous studies (8, 11).
The numbers of LKS+ cells in RARγ−/− BM were sig-
nifi  cantly elevated compared with that of RARγ+/+ BM 
(Fig. 3 A, P < 0.05). Interestingly and similar to the results 
Figure 1.  BM cells derived from 8-wk-old mice defi  cient for RAR𝗄 
have increased numbers of progenitors. (A) Numbers of CFU-GEMM 
produced per femur from 8-wk-old RARα+/+, RARα+/−, and RARα−/− 
mice (n = 4). (B) CFU-S content per femur from 8-wk-old RARα+/+, 
RARα+/−, and RARα−/− mice (n = 4). (C) Numbers of CFU-GEMM pro-
duced per femur from 8-wk-old RARγ+/+, RARγ+/−, and RARγ−/− mice 
(n = 4). *, P < 0.05 compared with RARγ+/+ BM (paired Student’s t test). 
(D) CFU-S content per femur from 8-wk-old RARγ+/+, RARγ+/−, and 
RARγ−/− mice (n = 4). *, P < 0.05 compared with RARγ+/+ BM; #, P < 0.05 
compared with RARγ+/− BM (paired Student’s t test). (E) Numbers 
of CMP per femur from 8-wk-old RARγ+/+ and RARγ−/− mice (n = 3). 
*, P < 0.05 compared with RARγ+/+ BM (paired Student’s t test). (F) Numbers 
of CLP per femur from 8-wk-old RARγ+/+ and RARγ−/− mice (n = 3). 
*, P < 0.05 compared with RARγ+/+ BM (paired Student’s t test). Data are 
presented as means ± SEM.
Figure 2.  BM cells derived from 8-wk-old mice defi  cient for RAR𝗄 
have reduced numbers of HSCs. Number of HSCs per femur of 8-wk-
old wild-type (+/+), RARγ+/−, RARγ−/−, and RARα−/− mice (n = 8–10). 
*, P < 0.05 compared with wild-type and RARα−/− BM; #, P < 0.05 com-
pared with RARγ+/− BM (paired Student’s t test). Data are presented as 
means ± SEM.1286  REGULATION OF HSCS BY RARγ | Purton et al.
obtained from the whole BM cell studies, the numbers of 
CFU-S formed per 500 LKS+ cells were signifi  cantly in-
creased from both RARγ+/− and RARγ−/− cells compared 
with that of RARγ+/+ cells (Fig. 3 B, P < 0.05). It is known 
that LKS+ cells are heterogeneous; therefore, we further in-
vestigated the LKS+ cell compartment of RARγ wild-type 
and null mice by phenotypic analysis of the CD34 and Flt3 
subsets within LKS+ cells, which discriminate between long-
term HSCs (CD34−Flt3−), short-term HSCs (CD34+Flt3−), 
and multipotent progenitors (CD34+Flt3+) (17). RARγ−/− 
LKS+ cells had signifi  cantly reduced percentages of CD34+Flt3+ 
cells, signifi   cantly increased content of CD34+Flt3−, and 
similar percentages of CD34−Flt3− compared with RARγ+/+ 
LKS+ cells (Fig. 3 C).
We further examined the functional capacity of LKS+ 
cells by performing competitive repopulating assays with 
LKS+ cells obtained from RARγ+/+, RARγ+/−, and 
RARγ−/− mutants (8). The numbers of repopulating units 
(RU) were estimated as previously described for comparison 
of HSC potential across the genotypes (18).
All populations had similar RU at 5 wk after BM trans-
plant (BMT) (Fig. 4 A). Thereafter, there was a progressive 
decline in RU from RARγ−/− LKS+ cells compared with 
RARγ+/+ LKS+ cells, resulting in a 2.5-fold reduction by 
3 mo and a signifi  cant 6.6-fold reduction by 6 mo (Fig. 
4, B and C; P < 0.05). Hence, RARγ−/− LKS+ cells had 
reduced long-term repopulating potential compared with 
RARγ+/+ LKS+ cells, results that are consistent with those 
obtained using unfractionated BM. The functional poten-
tial of the RARγ−/− LKS+ cells therefore did not   correlate 
Figure 3.  Properties of RAR𝗄 mutant LKS+ cells. (A) Number of 
LKS+ cells per femur from 8-wk-old RARγ+/+, RARγ+/−, and RARγ−/− mice 
(n = 7–12). *, P < 0.05 compared with RARγ+/+ and RARγ+/− LKS+ cells 
(paired Student’s t test). (B) Number of CFU-S produced per 500 LKS+ 
cells (n = 4). *, P < 0.05 compared with RARγ+/+ LKS+ cells; #, P < 0.05 
compared with RARγ+/− LKS+ cells (paired Student’s t test). Data are 
presented as means ± SEM. (C) Percentages of CD34 and Flt3 populations 
in LKS+ cells obtained from 8-wk-old RARγ+/+ and RARγ−/− mice 
(n = 5). *, P < 0.05 compared with RARγ+/+ LKS+ cells.
Figure 4.  RAR𝗄−/− LKS+ cells from 8-wk-old mice have reduced 
long-term competitive repopulating potential accompanied by 
  increased production of progenitor cells. (A–C) 1,000 LKS+ cells iso-
lated from RARγ+/+, RARγ+/−, or RARγ−/− BM were mixed with 105 con-
genic BM cells and transplanted into each lethally irradiated congenic 
recipient (n = 8). Peripheral blood was analyzed at (A) 5 wk, (B) 3 mo, and 
(C) 6 mo after BMT for donor-derived multilineage repopulating cells. 
The numbers of RU in each population are depicted below their 
respective graphs. *, P < 0.05 compared with RARγ+/+ LKS+ cells 
(paired Student’s t test). Data are presented as means ± SEM. (D) Apoptosis 
and cell cycle properties of RARγ mutant LKS+ cells (n = 3–5).JEM VOL. 203, May 15, 2006  1287
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with their CD34 phenotype, which is consistent with re-
ports by other investigators that CD34 subsets do not nec-
essarily provide an accurate measurement of HSC numbers 
in mutant mice or mice that are not in homeostatic condi-
tions (19–22). In contrast, RARα−/− LKS+ cells did not 
have altered repopulating potential compared with wild-
type LKS+ cells (Fig. S3, available at http://www.jem.
org/cgi/content/full/jem.20052105/DC1).
We further investigated properties of RARγ+/+ and 
RARγ−/− LKS+ cell populations to determine if altered sur-
vival or cell cycle properties could account for the reduced 
repopulating activity of the RARγ−/− LKS+ cells. There 
were no diff  erences in apoptosis, the percentages of cells in 
G0/G1 or the proportion of G0/G1 LKS+ cells that were in 
G0 in RARγ−/− LKS+ cells compared with RARγ+/+ LKS+ 
cells (Fig. 4 D). Hence, it did not appear that altered survival 
or cell cycle properties were contributing to the reduced 
long-term repopulating potential of RARγ−/− LKS+ cells.
BM obtained from 12-mo-old RAR𝗄 null mice have reduced 
CFU-GEMM colony-forming cell potential
RARγ−/− mice have been reported to exhibit early lethality 
from unknown causes (14). In our care, a small number of 
RARγ−/− mice have survived to 12 mo of age, which ap-
pears to be the maximum lifespan of these mutants. In these 
older mice, the PB and BM cellularities were slightly elevated 
compared with their wild-type age-matched littermates (Fig. 
5, A and B). The total CFC content was similar between all 
genotypes (Fig. 5 C). In contrast and opposite to that of 
8-wk-old RARγ−/− mice, the numbers of the immature 
CFU-GEMM were markedly reduced in RARγ−/− BM 
compared with their wild-type littermates (Fig. 5 D; 
P < 0.05). The CFU-GEMM content, the opposite of that 
of BM from 8-wk-old RARγ null mice (Fig. 2 D), is also 
consistent with enhanced diff  erentiation and reduced self-
  renewal capacity of RARγ HSCs, which, as the HSCs 
  exhaust over time, would likely result in reduced immature 
colony-forming cell potential in the BM of ageing mice.
ATRA-induced enhancement/maintenance of HSCs 
in ex vivo cultures requires RAR𝗄
We have previously shown that ATRA-treated LKS+ cells 
have enhanced long-term repopulating activity after 14 d of 
culture compared with LKS+ cells cultured without ATRA 
(8). We wished to determine if RARγ was the major RAR 
responsible for this maintenance of HSCs in ATRA-treated 
Figure 5.  Altered hematopoiesis in 12-mo-old mice defi  cient for 
RAR𝗄. (A) Peripheral blood cellularity of 12-mo-old mice (n = 3). (B) BM 
cellularity of 12-mo-old mice (n = 3). (A and B) WBC, white blood cells; 
RBC, red blood cells; PLT, platelets; HGB, hemoglobin; HCT, hematocrit. 
(C) Numbers of CFU-GEMM produced per femur from 12-mo-old 
RARγ+/+, RARγ+/−, and RARγ−/− mice (n = 3). *, P < 0.05 compared 
with RARγ+/+ BM (paired Student’s t test). (D) Numbers of total colonies 
produced per femur from 12-mo-old RARγ+/+, RARγ+/−, and RARγ−/− 
mice (n = 3). Data are presented as means ± SEM.1288  REGULATION OF HSCS BY RARγ | Purton et al.
ex vivo cultures and thus compared ATRA-treated cultures 
of RARγ+/+ and RARγ−/− LKS+ cells.
Consistent with our previous studies, neither RARγ+/+ 
nor RARγ−/− LKS+ cells cultured without ATRA for 14 d 
displayed any competitive repopulating potential (unpublished 
data). After 14 d of culture, ATRA-treated RARγ+/+ LKS+ 
cells comprised an average of 14% of peripheral blood cells in 
the transplanted mice, and these were multilineage repopu-
lating HSCs (Fig. 6). In contrast, ATRA-treated RARγ−/− 
LKS+ cells did not show any multilineage   repopulating po-
tential after 14 d of culture (Fig. 6). Furthermore, RARα−/− 
LKS+ cells cultured for 14 d with ATRA had similar com-
petitive repopulating potential (average 18%) compared with 
ATRA-treated wild-type LKS+ cells (Fig. 6). These data 
show that RARγ, but not RARα, is essential for the main-
tenance of HSCs in ATRA-treated ex vivo cultures.
RAR𝗄 signaling impacts on Notch1 expression
The aforementioned observations suggest that loss of RARγ 
results in an imbalance in HSC self-renewal decisions, result-
ing in increased commitment/diff  erentiation of HSCs into 
more mature progenitor cells. To determine if loss of RARγ 
altered the expression of genes previously shown to infl  uence 
HSC self-renewal, we investigated the expression of such 
genes in mRNA from freshly isolated RARγ+/+ and 
RARγ−/− LKS+ cells. We chose to investigate the possible 
deregulation of three diff  erent candidate genes (p21Cip1/Waf1, 
Notch1, and Hoxb4) based on both their known involve-
ment in HSC self-renewal (3, 23, 24) and also their previous 
links with retinoids in other settings (25–27).
Loss of RARγ did not alter expression of either p21Cip1/Waf1
or Hoxb4 in LKS+ cells (Table I A). In contrast, there 
was a signifi  cant reduction in the expression of Notch1 in 
RARγ−/− LKS+ cells (Table I A, P < 0.004), accompanied 
by reduced expression of hairy and enhancer of split 1 (Hes1), 
a measure of activated Notch1 (28) in these cells (Table I A).
To determine if activation of RARγ altered the expres-
sion of these genes, we compared the expression of p21Cip1/Waf1, 
Hoxb4, Notch1, and Hes1 in 3-d cultures of RARγ+/+ 
LKS+ cells treated for 3 d with or without ATRA. There 
were no changes in the expression of p21Cip1/Waf1 in LKS+ 
cells cultured with or without ATRA for 3 d (Table I B). In 
contrast, the expression of both Hoxb4 and Notch1 were 
signifi  cantly up-regulated in ATRA-treated LKS+ cells com-
pared with LKS+ cells cultured without ATRA (Table I B, 
P < 0.001). Interestingly, despite the absence of exogenous 
Notch1 ligands in these cultures, expression of Hes1 was also 
signifi  cantly increased in the 3-d ATRA-treated LKS+ cells 
compared with the LKS+ cells cultured without ATRA 
  (Table I B, P < 0.005).
We also compared the expression of these genes in cul-
tures of ATRA-treated RARγ+/+ and RARγ−/− LKS+ 
cells. The expression of p21Cip1/Waf1 and Hoxb4 was similar 
for both populations. In contrast, both Notch1 and Hes1 
were signifi   cantly down-regulated in ATRA-treated 
RARγ−/− LKS+ cells compared with RARγ+/+ LKS+ 
cells (Table I C, P < 0.05). In marked contrast, studies using 
RARα−/− LKS+ cell populations showed that Notch1 
and Hes1 were not down-regulated in RARα−/− LKS+ 
cells (Table I C).
Finally, we examined the expression of Notch1 and Hes1 
in 2-d cultures of immature BM cells transduced with 
RARγ1. Both Notch1 and Hes1 were signifi  cantly up-regu-
lated in RARγ1-overexpressing BM compared with those 
expressing the control vector (Table I D, P < 0.02). Interest-
ingly, overexpression of RARα did increase Notch1 expres-
sion compared with the control vector, but not to the 
magnitude of RARγ1 (Table I D, P < 0.05). Furthermore, 
Hes1 was not signifi  cantly increased in RARα-overexpress-
ing BM compared with the control vector (Table I D).
ATRA enhances the self-renewal of HSCs
Given that there was no diff  erence in survival or cell cycle 
properties of RARγ−/− LKS+ cells (Fig. 4), whereas both 
RARγ null LKS+ cells and unfractionated BM populations 
had increased numbers of progenitors accompanied by re-
duced numbers of HSCs (Figs. 1–4), our data are consistent 
with RARγ null HSCs undergoing reduced self-renewal and 
more diff   erentiation decisions. Furthermore, Notch1 and 
Hes1, a measure of activated Notch1, which has previously 
been shown to enhance HSC self-renewal (3), were signifi  -
cantly reduced in RARγ−/− LKS+ cell populations (Table I), 
further supporting that possibility. In addition, there was in-
creased expression of two genes previously associated with 
HSC self-renewal (Hoxb4 and Notch1) after 3 d of culture of 
wild-type LKS+ cells with ATRA compared with LKS+ cells 
cultured without ATRA (Table I B). In this study (Fig. 6) and 
in a previous report, we have also shown that there is   retention 
Figure 6.  ATRA does not enhance the repopulating ability of 
RAR𝗄−/− LKS+ cells. Shown are the competitive repopulation ability of 
wild-type (+/+), RARα−/−, and RARγ−/− LKS+ cells after 14 d of culture 
with ATRA. Data are expressed as the mean ± SEM donor cell multilin-
eage reconstitution in the peripheral blood of transplanted recipients 
(n = 8) analyzed at 6 mo after BMT. *, P < 0.05 compared with wild-type 
and RARα−/− LKS+ cells (paired Student’s t test).JEM VOL. 203, May 15, 2006  1289
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of repopulating potential in wild-type LKS+ cells cultured 
with ATRA for 14 d compared with loss of repopulating abil-
ity in LKS+ cells cultured in the same conditions but without 
ATRA (8). We now show that RARγ is required for these 
eff  ects (Fig. 6). Therefore, we wished to determine if ATRA 
was enhancing the self-renewal of wild-type HSCs.
The HSC compartment has been shown to be heteroge-
neous, comprised of a hierarchy of HSCs that can be identi-
fi  ed by their functional capacity. The most immature HSC in 
this hierarchy is capable of sustaining hematopoiesis through-
out serial transplantation (Fig. 7 A) (29, 30). Therefore, to 
determine if ATRA enhanced self-renewal of these highly 
primitive, serially transplantable HSCs, we investigated the 
serial BMT potential of LKS+ cells cultured with or without 
ATRA for 3 d compared with noncultured LKS+ cells using 
competitive repopulation assays.
The long-term, multilineage, competitive repopulating 
HSC potential (6 mo after BMT) of 1,000 freshly isolated 
LKS+ cells or their cultured equivalents was fi  rst measured in 
primary lethally irradiated recipients. BM cells from these 
mice were then pooled within treatment groups and injected 
into secondary lethally irradiated recipients. The multi-lin-
eage repopulating potential of HSCs in secondary recipients 
and each subsequent serial transplant recipient was measured 
at 3 mo after BMT, then BM from these mice were pooled 
and injected into the next serial transplant recipients.
The donor cell chimerism of HSCs cultured with or 
without ATRA for 3 d increased relative to the control (non-
cultured) LKS+ cells (% donor cell chimerism, mean ± SEM 
control: 59.7 ± 17, no ATRA: 74.91 ± 10.75, ATRA: 
73.98 ± 10.95, Fig. 7 B). Interestingly, in the secondary re-
cipients of the HSCs cultured without ATRA, the donor cell 
chimerism was signifi  cantly reduced compared with the con-
trol, suggesting that there was enhanced diff  erentiation into 
more mature HSCs within the HSC hierarchy. In contrast, 
the reconstituting ability of the 3-d ATRA-treated LKS+ 
cells remained signifi  cantly higher in the secondary recipients 
compared with that of recipients of control (noncultured) 
LKS+ cells, even during subsequent transplantation (Fig. 7 B). 
Of note, all quaternary recipients of the 3-d ATRA-treated 
Table I.  Notch1 expression is altered by RARγ signaling
A Freshly isolated LKS+
RAR𝗄+/+ RAR𝗄−/− RAR𝗂−/−
p21 28.07 ± 3.12 26.99 ± 2.77   ND
Hoxb4   3.12 ± 0.46   3.73 ± 0.23   ND
Notch1 315.4 ± 45.1 192.59 ± 21.6a   1,065 ± 90.8b
Hes1 96.74 ± 5.26   70.00 ± 12.7a 83.44 ± 9.35
B 3-d cultured wild-type LKS+
No ATRA ATRA
p21    5.38 ± 0.38 4.79 ± 0.55
Hoxb4    4.05 ± 0.48 12.39 ± 0.67c
Notch1 122.59 ± 2.19 290.55 ± 14.2c
Hes1    1.39 ± 0.23 8.02 ± 1.39c
C 3-d ATRA-treated LKS+
RAR𝗄+/+ RAR𝗄−/− RAR𝗂−/−
p21    4.79 ± 0.55   4.25 ± 0.27   ND
Hoxb4  12.39 ± 0.67  11.27 ± 1.43   ND
Notch1 290.55 ± 14.2 205.94 ± 14.2a 361.9 ± 32.1
Hes1    8.02 ± 1.39      5.32 ± 0.57a   11.48 ± 1.00b
D Gene overexpression studies
Control RAR𝗄1 RAR𝗂
Notch1 122.12 ± 8.93 352.94 ± 55.7d,e 202.42 ± 18.7d
Hes1 10.59 ± 0.65 16.49 ± 2.51d,e 10.80 ± 1.37
The levels of expression of the different genes were quantitated by Q-RT-PCR and are given as arbitrary units relative to β2-microglobulin for each of the genes. Shown 
are the relative expression of HSC self-renewal–associated genes in (A) freshly isolated RARγ+/+, RARγ−/−, and RARα−/− LKS+ cells; (B) 3-d cultured wild-type LKS+ cell 
populations; (C) 3-d ATRA-treated RARγ+/+, RARγ−/−, and RARα−/− LKS+ cells; and (D) control, RARγ1-, or RARα-overexpressing primitive hematopoietic cells. LKS+, 
lineage−, c-kit+, Sca-1+ (HSC enriched). The data represent the mean ± SEM of three different experiments for each population tested. ND, not determined.
aP < 0.05 RARγ−/− LKS+ vs. RARγ+/+ LKS+ and RARα−/− LKS+ cells.
bP < 0.05 RARα−/− LKS+ vs. RARγ+/+ LKS+ cells.
cP < 0.05 ATRA vs. No ATRA treatment.
dP < 0.05 RARγ1 or RARα vs. control overexpressing cells.
eP < 0.05 RARγ1 vs. RARα-overexpressing cells.1290  REGULATION OF HSCS BY RARγ | Purton et al.
LKS+ cells had signifi  cant multilineage donor reconstituting 
ability, with donor repopulating levels in quaternary BMT re-
cipients of 20.1 ± 8.6% (Fig. 7 B). In marked contrast, no 
quaternary BMT recipient of noncultured LKS+ cells or LKS+ 
cells cultured without ATRA for 3 d had detectable donor cell 
reconstitution (Fig. 7 B). The strikingly increased serial trans-
plantability of the ATRA-treated LKS+ cells over that of the 
noncultured LKS+ cells, which would have the highest serial 
transplant potential if self-renewal was not enhanced, indi-
cated that pharmacological stimulation with ATRA enhanced 
the self-renewal of HSCs in the 3 d ex vivo cultures.
D  I  S  C  U  S  S  I  O  N 
In these studies, we show that the two major RARs expressed 
in hematopoietic cells, RARα and RARγ, have distinct 
roles in the regulation of immature progenitors and HSCs. 
We demonstrate that RARγ−/− mice have increased num-
bers of committed hematopoietic progenitors (Fig. 1, C–F) 
and that this is accompanied by signifi  cantly reduced num-
bers of long-term repopulating HSCs (Figs. 2 and 4 C). These 
abnormalities are not observed in RARα−/− mice (Fig. 2 and 
Fig. S3). The survival and cell cycle properties of enriched 
populations of RARγ−/− HSCs were not diff  erent to those 
of RARγ+/+ HSCs, suggesting that the impaired repopulat-
ing potential of the RARγ−/− HSCs were not the result of 
altered apoptosis or cycling of these HSCs (Fig. 4 D). Fur-
thermore, we show that ATRA enhances HSC self-renewal 
(Fig. 7 B) and that RARγ, but not RARα, is required for the 
potentiating eff  ects of ATRA in extended ex vivo culture 
systems (Fig. 6).
These data collectively demonstrate that RARγ is a key 
physiological regulator of HSCs. In RARγ+/+ HSCs, there is 
a balance between HSC self-renewal and diff  erentiation deci-
sions. When treated with pharmacological levels of ATRA, 
the HSCs undergo more self-renewal divisions (Fig. 7 B). In 
contrast, our observations that RARγ−/− mice display in-
creased numbers of committed progenitors (Fig. 1, C–F, and 
Fig. 3 B) and reduced numbers of long-term repopulating 
HSCs (Figs. 2 and 4 C) suggests that the HSCs from RARγ−/− 
mice display an imbalance between self-renewal and diff  eren-
tiation, favoring diff  erentiation divisions. Furthermore, loss of 
RARγ signaling results in the inability of the HSCs to main-
tain repopulating ability in response to ATRA treatment in 
ex vivo culture (Fig. 6). In addition, the haplo-insuffi   ciency 
shown by RARγ+/− HSCs, which had an intermediate phe-
notype between that of RARγ−/− and RARγ+/+ HSCs 
(Figs. 1–4), also underscores the importance of RARγ signal-
ing in HSCs. These data demonstrate that RARγ is a key 
regulator of HSC homeostasis, infl  uencing the balance be-
tween self-renewal and diff  erentiation decisions of the HSC.
In a previous investigation, Labrecque et al. reported that 
RARγ null mice do not have altered numbers of progenitor 
cells (9). The major diff  erence between the previous study 
and ours is that they used fetal BM (18.5 dpc), whereas we 
used BM from adult (8-wk-old) mice. In addition, in contrast 
with the increased numbers of progenitors in 8-wk-old mice, 
we observed signifi  cantly reduced numbers of progenitors in 
12-mo-old RARγ null mice. These contrasting data there-
fore demonstrate that the age of the mice studied can also be 
crucial to the results obtained as can the subsequent interpre-
tation of that data, when investigating hematopoietic defects 
such as that observed in RARγ−/− mice.
The eff  ects of RARγ were specifi  c to this RAR, as 
RARα null mice did not display any HSC defects (Fig. 2), 
and RARα null HSCs retained their ability to self-renew in 
ex vivo culture in response to ATRA treatment (Fig. 6). 
RARβ2 was not apparently important to the HSC defect 
observed in RARγ−/− mice as it was expressed at equal levels 
in both RARγ+/+ and RARγ−/− LKS+ cells (unpublished 
data). Collectively, these data highlight the importance and 
nonredundant role of RARγ in mediating the HSC self-
  renewing eff  ects induced by ATRA treatment.
Figure 7.  ATRA enhances the serial transplantability of cultured 
HSCs. (A) Experimental protocol for detecting the most primitive HSCs 
by serial transplantation. (B) The data show the increased serial trans-
plantability of LKS+ cells after 3 d of culture with ATRA compared with 
noncultured LKS+ or LKS+ cells cultured without ATRA for 3 d. Data are 
expressed as the mean ± SEM donor cell reconstitution in the peripheral 
blood of transplanted recipients (six mice per group) analyzed at 6 mo 
(primary transplant) and 3 mo (subsequent serial transplants) after BMT. 
*, P < 0.05; #, P < 0.01 compared with noncultured LKS+ cells (paired 
 Student’s  t test).JEM VOL. 203, May 15, 2006  1291
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In hematopoiesis, ATRA is predominantly known as a dif-
ferentiating agent, potently inducing the terminal   granulocytic 
maturation of primary leukemia cells from patients with 
acute promyelocytic leukemia (31–33). We have also shown 
that, in contrast with its potentiating eff  ects on HSC self-
  renewal, ATRA also has potent eff  ects in enhancing normal 
primary granulocyte diff  erentiation in vitro (11). RARα 
  appears to be the most potent of the three receptors in induc-
ing these eff  ects, as shown by its genetic involvement in acute 
promyelocytic leukemia (34), and it has the most dramatic 
eff  ects on neutrophil diff  erentiation from both maturing 
committed granulocyte progenitors and more immature 
  progenitors (35, 36).
In the current study, we have confi  rmed the predominant 
role of RARα in granulopoiesis, as RARα-overexpressing BM 
cells rapidly diff   erentiated down the granulocytic pathway 
compared with both the control and RARγ1-overexpressing 
cells (Fig. S1). However, despite these profound eff  ects  of 
RARα in enhancing primitive cell diff  erentiation down the 
granulocyte lineage, RARα does not appear to have a role in 
regulating HSCs, as we did not observe any defects in the num-
bers of primitive progenitors or HSCs in RARα null mice.
It was of interest to determine whether RARγ signaling 
aff  ected other genes known to induce HSC self-renewal (3, 
23, 24). Despite having previously been reported to have an 
retinoic acid response element in its promoter region (37), ex-
pression of the cyclin-dependent kinase inhibitor p21Cip1/Waf1 
was not altered by ATRA treatment (Table I B), nor was 
it deregulated in RARγ−/− LKS+ cells (Table I, A and C). 
We have also previously shown that p27Kip1, which has roles 
in HSC homeostasis (38, 39), is in part required for RARα-, 
but not RARγ-, mediated responses (36); therefore p27Kip1 
is also unlikely to be involved in RARγ-induced HSC 
self-renewal.
The expression of Hoxb4 was markedly up-regulated in 
ATRA-treated LKS+ cells (Table I B), consistent with previ-
ous studies showing that retinoids regulate Hox gene expres-
sion in other organs (40). Despite this increase, however, 
there were no diff  erences in Hoxb4 expression between the 
RARγ−/− and RARγ+/+ LKS+ cells (Table I, A and C); 
hence, Hoxb4 is not likely a target gene of RARγ.
In contrast with Hoxb4 and p21Cip1/Waf1, Notch1 expression 
was markedly increased in both ATRA-treated RARγ+/+ 
LKS+ cells (Table I B) and RARγ1-  overexpressing BM cells 
(Table I D) and signifi  cantly decreased in RARγ−/− LKS+ cells 
compared with wild-type LKS+ cells (Table I, A and C). This 
was accompanied by similarly altered levels of expression of 
Hes1, a measure of Notch-mediated signaling, in these popula-
tions (Table I). In contrast, Notch1 and Hes1 were not signifi  -
cantly down-regulated in RARα−/− LKS+ cells (Table I).
Of interest, it has recently been shown that Notch sig-
naling is down-regulated as HSCs diff  erentiate (41). Given 
both our observations of the reduced self-renewal/enhanced 
diff  erentiation of RARγ−/− HSCs and the reduced expres-
sion of Notch1 in RARγ−/− LKS+ cells, it is possible that 
altered Notch1 signaling was contributing to the HSC de-
fects observed in RARγ null mice. Likewise, it is possible 
that increased signaling of Notch1 was contributing to the 
enhanced HSC self-renewal observed in ATRA-treated cul-
tures of wild-type HSCs (Fig. 7 B). However, unlike RARγ 
null mice, Notch1 knockout mice do not have an HSC de-
fect (7); hence, altered Notch1 is unlikely to be the main 
contributing factor to the HSC defects observed in RARγ 
null mice.
Of therapeutic relevance is that HSCs were induced to 
self-renew in simple ex vivo cultures using pharmacological 
levels of ATRA, which is approved for use. Interestingly, a 
recent report demonstrated the potential benefi  cial use of 
ATRA for the expansion of human HSCs (42). Our studies 
demonstrating the diff  erent roles of the RARs and especially 
the critical role for RARγ in regulating HSCs now suggest 
that specifi  cally targeting RARγ could further improve on 
the ATRA-mediated ex vivo expansion of HSCs. Additional 
studies are therefore warranted to further investigate the ef-
fects of RAR-specifi  c ligands in enhancing the expansion of 
HSCs for therapeutic purposes.
MATERIALS AND METHODS
Mice. For serial transplant studies, donor mice were C57BL/6J (CD45.2+) 
and recipient mice were B6.SJL-PtprcaPep3b/BoyJ (herein referred to as 
Ptprca; CD45.1+), both were obtained from Animal Resources Centre, Perth, 
WA, Australia. RARα (13) and RARγ (14) mutant mice were backcrossed 
10 generations onto the C57BL/6J background for these studies. Except 
when otherwise described, all mice were used between 8 and 10 wk of age. 
All experiments performed were approved by the Peter MacCallum Cancer 
Centre animal experimentation ethics committee and were conducted in 
strict compliance to the regulatory standards of the Australian Code of Prac-
tice for the Care and Use of Animals for Scientifi  c Purposes.
Quantitation of progenitor cell content in RAR mutant mice. The 
number of CFU-GEMM per 5 × 104 BM cells and CFU-S from 5 × 105 BM 
and 500 LKS+ cells were measured as described previously (11). The numbers 
of BM CMP and CLP were measured as described previously (38, 43, 44).
Limiting dilution assay. The frequency of HSCs in whole BM obtained 
from RARγ+/+, +/−, or −/− mice was determined by Poisson statistics 
using the limiting dilution assay described previously (16). Recipient mice 
were lethally irradiated with a total dose of 10 Gy, given in two equal frac-
tions 3 h apart, and delivered by two opposing 137Cs sources (Gammacell 40, 
Atomic Energy of Canada) on the day of transplant. Recipient CD45.1+ 
mice (8–10 mice per group) were injected with 104, 5 × 104, 2 × 105 or 
2 × 106 BM cells obtained from the CD45.2+ RARγ mice together with 
2 × 105 Ptprca/C57BL/6J (CD45.2+/CD45.1+) congenic BM. Mice were 
assessed for CD45.2+/CD45.1− donor cell peripheral blood reconstitution 
in lymphoid and myeloid lineages at 6 mo posttransplant as described previ-
ously (8, 38).
LKS+ cell culture and transplantation studies. LKS+ cells and LKS− 
cells were isolated and cultured in Iscove’s modifi  ed essential medium 
  containing 20% FBS, 100 ng/ml of each recombinant mouse (rm) SCF, 
  recombinant human (rh) IL-6, rhFlt-3L, and 10 ng/ml rhIL-11 (Peprotech, 
Inc.) as described previously (11). Cultures were supplemented with or 
without 1 μM ATRA (Sigma-Aldrich).
Primary competitive repopulating potential of RARγ mutant LKS+ 
cells was performed as described previously (8). The numbers of RU were 
assessed according to the method of Harrison et al. (18). In brief, donor 
RU = % donor x competitor RU/(100 − % donor), where competitor 
RU = number of competing BM (×105), in this situation = 1.1292  REGULATION OF HSCS BY RARγ | Purton et al.
Primary competitive repopulating transplants of noncultured and 3-d 
cultured LKS+ cells were performed as described previously (8). Donor mice 
were C57BL/6J (CD45.2+), and recipient mice were Ptprca (CD45.1+), 
both obtained from Animal Resources Centre. Multilineage peripheral 
blood cell reconstitution by CD45.2+ donor cells was monitored at 
6 mo posttransplant.
For serial transplant studies, the primary recipient mice were killed at 
7 mo posttransplant and the contents of their femurs were pooled within the 
respective groups. Irradiated secondary Ptprca recipients received BM cells 
equivalent to one third of the femoral contents of the primary recipients. 
Donor (CD45.2+) cell reconstitution was assessed at 3 mo posttransplant for 
the secondary and subsequent recipients, then these recipients were killed 
and the contents equivalent to one tenth of a femoral content were injected 
into new lethally irradiated Ptprca recipients.
Additional properties of LKS+ cells obtained from RAR𝗄 null mice. 
Apoptosis was measured in LKS+ cells by the annexin V–FITC apoptosis 
detection kit (Becton Dickinson), according to the manufacturer’s instruc-
tions. Cell cycle analysis of LKS+ cell populations was performed as de-
scribed previously (38). The proportions of CD34 and Flt3 populations in 
LKS+ cells were measured as described previously (17).
RNA extraction and quantitative RT-PCR. Extraction of mRNA and 
synthesis of cDNA were performed as described previously (45). All reac-
tions were conducted using an ABI Prism 7000 Sequence Detection System 
(Applied Biosystems). 8 μl cDNA (1:10 dilution) was combined with 10 μl 
SyBr green PCR Master Mix (Applied Biosystems) and 200 nm each of 
sense and antisense oligonucleotides (Geneworks). PCR conditions were as 
follows: 50°C for 2 min and 95°C for 10 min, followed by 45 cycles at 95°C 
for 15 s and 60°C for 1 min. Expression of all genes were compared with β2-
microglobulin to determine relative levels of mRNA transcripts. All primers 
used in these studies are given in Table S2 (available at http://www.jem.
org/cgi/content/full/jem.20052105/DC1).
Statistics. The results are expressed as the mean ± SEM for n given samples. 
Data were analyzed using the paired two-tailed Student’s t test, with any 
p-value ≤0.05 being considered signifi  cant.
Online supplemental material. Fig. S1 shows the eff  ects of overexpres-
sion of RARα or RARγ1 on primitive BM cells; Fig. S2 shows the lim-
iting dilution graphs for calculation of HSC numbers in RARγ mutants; 
and Fig. S3 shows the repopulating potential of RARα−/− and RARα+/+ 
LKS+ cell populations. Table S1 shows the expression of RARs in LKS+ 
and LKS− cell populations. Table S2 provides real-time primer sequences 
used in these studies. Online supplemental material, including   supplemental 
Materials and methods, is available at http://www.jem.org/cgi/content/
full/jem.20052105/DC1.
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